Compare Mesoblast Limited (MESO) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while First Trust NASDAQ 100 Technology Index Fund trades at $310.02. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | QTEC | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.96 | $335.74 |
52-Week Low | $12.88 | $207.03 |
Enterprise Value | $2.17B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
